Category: Squamous Cell Carcinoma

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016

Cancer Patients Value Quality of Life Over Symptom Management

In October at their headquarters in New York City, CancerCare, a national organization that provides free support and financial services to anyone touched by cancer, held a roundtable discussion on “Improving the Quality of Life for Lung Cancer Patients”. It featured key opinion leaders and lung cancer advocates who discussed the importance of an all-inclusive… Read More

Posted by Dr. Guneet Walia on March 10th, 2016

Lung Cancer in Women: Lets do something about it!

Bonnie J. Addario Lung Cancer Foundation partners with the American Lung Association to fund $250,000 on innovative and transformational research to defeat lung cancer in women An unfortunate and often unknown fact is that lung cancer is the leading cancer killer in women, estimated to be the cause of 1 in 4 female cancer deaths… Read More

Posted by Dr. Guneet Walia on February 25th, 2016

Today is World Cancer Day. Here’s how YOU can #BeTheSolution!

Bonnie J. Addario Lung Cancer Foundation Launches $180,000 Crowdsourcing Challenge to Increase Clinical Trial Patient Enrollment. Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd, encouraging innovators from both within and more importantly, outside healthcare… Read More

Posted by Dr. Guneet Walia on February 4th, 2016

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients

The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments. ALCF works everyday to educate patients and their families on the latest advancements, encourage participation in clinical trials and fund life-saving research on… Read More

Posted by Dr. Guneet Walia on December 18th, 2015

FDA approves Necitumumab for Squamous NSCLC

The US FDA today approved Necitumumab or Portrazza in combination with two forms of chemotherapy – gemcitabine (Gemzar) and cisplatin (Platinol)- for the treatment of advanced, metastatic squamous non-small cell lung cancer (NSCLC) patients who have not been previously treated for their advanced lung cancer. Mechanism of Action: Necitumumab or Portrazza is a human monoclonal… Read More

Posted by Dr. Guneet Walia on November 24th, 2015

Expanded FDA Drug Approval Increases Lung Cancer Survivability, Hope for a Cure

Nivolumab now approved for both squamous and non-squamous NSCLC patients Diagnostic test to detect PDL1 expression also granted approval October 9, 2015. The most common type of lung cancer, non-small cell lung cancer (NSCLC) is divided into two subtypes- squamous cell and non-squamous cell lung cancer- depending on the specific kinds of cells found in the… Read More

Posted by Dr. Guneet Walia on October 9th, 2015

Got Young Lungs?

In July, 2014 we launched an international study to understand why young people under the age of 40 were increasingly being diagnosed with lung cancer- the Genomics of Young Lung study, the FIRST ever study to prospectively characterize the clinical characteristics and genomic alterations of young lung cancer. Our early data shows that 75% of all patients under 40 have… Read More

Posted by Dr. Guneet Walia on October 5th, 2015

MET Its Match? Targeted Therapy for Mutations in the MET Gene

We are progressively moving from treating lung cancer as one disease, to an era of lung cancer being a collection of separate subtypes, each driven by an oncogenic mutation that contributes to cancer initiation, progression and metastasis. We are now filling out the lung cancer pie-chart for these individual subtypes, and beginning to understand each… Read More

Posted by Dr. Guneet Walia on October 3rd, 2015